Sarkomycin
Sarkomycin is a glutathione-targeting cytotoxic agent and antibacterial agent. Sarkomycin forms an addition product with glutathione, thereby reducing intracellular glutathione levels. Sarkomycin can induce cytoplasmic vacuolation, mitochondrial damage, cytoplasmic deformation, metaphase arrest, chromosomal abnormalities, nuclear degeneration, and nuclear fragmentation; it also modulates amino acid metabolism. Sarkomycin also inhibits anaerobic fermentation in affected cells in mice and inhibits cell growth in tissue culture, leading to the disappearance of mitotic cells, cell degeneration, and cell detachment from the glass surface. Sarkomycin can be used in research related to Yoshida ascites tumor, Ehrlich ascites tumor, Ehrlich carcinoma, and Yoshida rat sarcoma.
For research use only. We do not sell to patients.
- CAS No.: 489-21-4
- Formula: C7H8O3
- Molecular Weight:140.14
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Active forms of Sarkomycin (1000, 200, 100 mcg/mL; 80 minutes) strongly inhibit anaerobic glucose fermentation in Ehrlich ascites carcinoma cells, with 80-90% inhibition at 1000 mcg/mL, 20-40% inhibition at 200 mcg/mL, and 0% inhibition at 100 mcg/mL for Sy and SI[2].
Sarkomycin exhibits equal activity against Ehrlich carcinoma cells as sarkomycin-INH, with Ehrlich carcinoma cells being 10-20 times more sensitive to sarkomycin than Yoshida rat sarcoma cells, while Yoshida rat sarcoma cells are approximately 2.5 times more sensitive to sarkomycin-INH than to sarkomycin[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Sarkomycin (3.5 mg; i.p.; single dose) induces rapid, progressive cytological damage and marked alterations in free amino acid levels, including de novo glutamine appearance, in Ehrlich ascites tumor cells and fluid in A/He mice[1].
Sarkomycin (3.5 mg; i.p.; single dose) induces identical rapid cytological and amino acid alterations in Ehrlich ascites tumor cells and fluid in C57BL mice as observed in A/He mice[1].
Sarkomycin (30 mg/100 gm; i.p.; single dose) does not impair the ability of Yoshida ascites tumor cells to take up and convert exogenous glutamine, while altering specific cellular amino acid levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pacific Farms Wistar (WP) (175 gm, Yoshida ascites tumor transplanted intraperitoneally 5 days prior)[1]
-
Dosage:50 mg
-
Administration:i.p.; single dose
-
Result:Reduced mitotic figures such that no normal mitotic figures were present by 120 minutes.
Induced cytoplasmic blebbing, chromosomal clumping, and scattering in metaphase cells by 30 minutes.
Caused severe cytoplasmic distortion, mitotic arrest at metaphase, and nuclear abnormalities by 60 minutes.
Resulted in over 50% of cells showing pyknotic chromatin aggregates by 120 minutes.
Greatly elevated cellular glutamine levels and induced glutamine appearance in ascitic fluid by 30 minutes, with further increases by 300 minutes.
Triggered progressive mitochondrial degeneration and marked intraperitoneal cellular reaction by 300 minutes.
-
Animal Model:Pacific Farms Wistar (WP) (Yoshida ascites tumor transplanted intraperitoneally 5 days prior)[1]
-
Dosage:30 mg/100 gm
-
Administration:i.p.; single dose
-
Result:Preserved tumor cells' ability to take up labeled glutamine and convert it to glutamic acid.
Caused slight decreases in aspartic acid and glutathione levels in cells.
Induced appearance of a new unidentified ninhydrin-reactive substance in cells.
-
Animal Model:A/He (35 gm average weight, Ehrlich ascites tumor transplanted intraperitoneally 48 hours prior)[1]
-
Dosage:3.5 mg
-
Administration:i.p.; single dose
-
Result:Induced cytoplasmic blisters, clumped/sticky chromosomes in metaphase cells, and chromonema-like structures in resting nuclei by 5 minutes.
Caused severe cytoplasmic blebbing and peaked abnormal nuclear structures by 10 minutes.
Triggered abnormal nucleus coalescence and degeneration, and elevated taurine levels in ascitic fluid by 20 minutes.
Resulted in extensive cytoplasmic damage and karyorrhexis, and marked elevations in cellular glutamine, valine, leucine, tyrosine, and lysine levels, plus elevated ascitic fluid glutamine, aspartic acid, taurine, and valine levels with decreased alanine and glycine levels by 40 minutes.
Eliminated all damaged cells, leaving a small number of normal-appearing tumor cells between 60 and 120 minutes.
Induced de novo glutamine appearance in cells, decreased glutathione levels, increased valine and leucine levels, and a new unidentified ninhydrin-reactive substance by 5 minutes.
-
Animal Model:C57BL (Ehrlich ascites tumor transplanted intraperitoneally 3 days prior)[1]
-
Dosage:3.5 mg
-
Administration:i.p.; single dose
-
Result:Induced cytoplasmic damage and nuclear abnormalities.
Triggered appearance of glutamine in cells, decreased glutathione levels, increased valine and leucine levels, and presence of an unidentified ninhydrin-reactive substance.
Chemical Information
-
CAS No. 489-21-4
-
Molecular Weight 140.14
-
Formula C7H8O3
-
SMILES
OC([C@H]1C(C(CC1)=O)=C)=O
-
Structure Classification
-
Initial Source
Streptomyces erythrochromogenes
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Nuclear DNA counterstaining and nuclear morphology staining
Nuclear DNA counterstaining uses DNA-binding fluorescent dyes to visualize nuclei and chromatin so that nuclei can be located, counted, segmented, and evaluated for morphology; Hoechst 33342, DAPI, propidium iodide, and DRAQ5 are commonly reported nuclear stains, while live-cell DNA labeling is better supported for Hoechst dyes and DRAQ5 than for propidium iodide in intact viable cells. Nuclear morphology staining can detect apoptosis-associated nuclear changes, including chromatin condensation, nuclear shrinkage, nuclear fragmentation, reduced nuclear area/perimeter/axis length, and increased nuclear fluorescence intensity; these morphology readouts have been compared with apoptosis markers such as TUNEL and caspase-3 immunofluorescence.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)